Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug may get your gut moving faster after hernia repair

NCT ID NCT05985343

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether sugammadex, a drug used to reverse muscle relaxants after surgery, could help patients regain bowel function faster than standard care. 184 adults undergoing open abdominal wall reconstruction for ventral hernia were randomly assigned to receive either sugammadex or the usual reversal drugs. The main goal was to see how quickly patients could eat solid food and have their first bowel movement after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sugammadex
What this could lead to
If it works, sugammadex could help patients recover bowel function faster after abdominal wall surgery, reducing hospital stays.
What could go wrong
This is a small, completed Phase 4 trial with 184 patients, so results may not apply to everyone. Sugammadex can cause allergic reactions in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

184 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults \>18 years old * Patients requiring an open ventral hernia repair with retromuscular mesh placement and at least one myofascial advancement flap * Hernias with fascial defects \< 20cm wide * Non-emergent cases Exclusion Criteria: * Known serious or severe hypersensitivity reaction to sugammadex or any of the ingredients in sugammadex. * Hernias with fascial defects \> 20cm wide * Concomitant treatment with a strong or moderate cytochrome P450 3A4 inhibitor (e.g., Ketoconazole and other anti-fungals, Clarithromycin, HIV protease inhibitors, diltiazem, erythromycin, verapamil) or strong CYP3A4 inducers (e.g., rifampin). * Known small bowel obstruction (SBO) at the time of hernia repair * Suspected SBO or at risk of recurrent SBO at the time of hernia repair - at the discretion of the staff surgeon. * Nasogastric (NG), orogastric (OG), or gastric (eg. PEG) in place at the time of hernia repair and left in beyond the morning of the first postoperative day. * Patients with a stoma. * Cancer with increased risk of gastro-duodenal perforation (e.g., infiltrative gastrointestinal tract malignancy, recent gastrointestinal tract surgery, diverticular disease including diverticulitis, ischemic colitis, or concomitantly treated with bevacizumab) - at the discretion of the staff surgeon. * Disorder that could alter the integrity of the gastrointestinal lining (e.g., Crohn's disease) - at the discretion of the staff surgeon. * Severe hepatic failure (Child-Pugh Class C). * Clinically relevant hepatic failure (e.g. cirrhosis) - at the discretion of the staff surgeon. * Severe renal failure (GFR\<30ml/min, on dialysis, or have an arteriovenous fistula, indwelling hemodialysis catheter or peritoneal dialysis catheter) - at the discretion of the staff surgeon. * Pregnant or planning to become pregnant during study period. * Breastfeeding or planning to breastfeed during study period. * Clinically relevant alteration of the blood-brain-barrier - at the discretion of the staff surgeon. * Other contraindication to sugammadex as documented by a physician. * Unable to give informed consent; vulnerable populations; non-English speaking. * Emergent operation. * Undergoing minimally invasive approaches. * Undergoing repair with mesh placed in a position other than retromuscular. * Chronic opioid users, as defined by the daily use of opioids for at least 90 days within the past year * Inability to safely extubate the patient at the end of the surgery for any reason, as determined by the operative team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hernia, ventral are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hernia, Ventral ileus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic Center for Abdominal Core Health

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.